scholarly article | Q13442814 |
P50 | author | Hyun Woong Lee | Q57321514 |
Jun Yong Park | Q58221011 | ||
Sang Hoon Ahn | Q63436666 | ||
Kwang-Hyub Han | Q63436668 | ||
Young Joon Yoon | Q83971708 | ||
Chae Yoon Chon | Q114727137 | ||
Young Myoung Moon | Q114727155 | ||
P2093 | author name string | Do Yun Lee | |
Ja Kyung Kim | |||
P2860 | cites work | Global cancer statistics, 2002 | Q27860562 |
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver | Q29616866 | ||
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases | Q33344056 | ||
Low serum alpha-fetoprotein level in patients with hepatocellular carcinoma as a predictor of response to 5-fu and interferon-alpha-2b | Q33489279 | ||
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials | Q34068152 | ||
Prognostic prediction and treatment strategy in hepatocellular carcinoma. | Q34547469 | ||
Treatment of non-resectable hepatocellular carcinoma | Q35020886 | ||
Treatment outcome of transcatheter arterial chemoinfusion according to anticancer agents and prognostic factors in patients with advanced hepatocellular carcinoma (TNM stage IVa). | Q38516034 | ||
Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients | Q43850818 | ||
Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein | Q44062778 | ||
Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy | Q44232425 | ||
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? | Q51815043 | ||
Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump | Q67531478 | ||
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein | Q73335123 | ||
Intermittent hepatic arterial infusion of high-dose 5FU on a weekly schedule for liver metastases from colorectal cancer | Q73793465 | ||
Efficacy of an implanted drug delivery system for advanced hepatocellular carcinoma using 5-fluorouracil, epirubicin and mitomycin C | Q78246167 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | fluorouracil | Q238512 |
cisplatin | Q412415 | ||
chemotherapy | Q974135 | ||
P304 | page(s) | 129-137 | |
P577 | publication date | 2007-07-01 | |
P1433 | published in | Cancer | Q326041 |
P1476 | title | Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma | |
P478 | volume | 110 |
Q87401733 | A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis |
Q35833016 | A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma |
Q44681461 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy |
Q53399296 | Adjuvant hepatic arterial infusional chemotherapy with 5-fluorouracil and cisplatin after curative resection of hepatocellular carcinoma. |
Q45358377 | Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus-related advanced hepatocellular carcinoma. |
Q53379427 | Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. |
Q42332098 | Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma? |
Q90366618 | Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis |
Q47775953 | Chemotherapy for hepatocellular carcinoma: current status and future perspectives |
Q89750132 | Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: |
Q53356745 | Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. |
Q43485596 | Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. |
Q38032906 | Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy |
Q57292656 | Cytotoxicity and Toxicity Evaluation of Xanthone Crude Extract on Hypoxic Human Hepatocellular Carcinoma and Zebrafish () Embryos |
Q35553137 | Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread |
Q37039311 | Doxorubicin and 5-fluorouracil resistant hepatic cancer cells demonstrate stem-like properties |
Q35890647 | Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis |
Q35025403 | Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma |
Q53289466 | Evaluation of ERCC1 Expression for Cisplatin Sensitivity in Human Hepatocellular Carcinoma |
Q34390215 | Future perspectives on the treatment of hepatocellular carcinoma with cisplatin |
Q38161384 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in Japan |
Q37068236 | Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis |
Q38410821 | Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma |
Q33404756 | Hepatic intra-arterial chemotherapy in patients with advanced primary liver tumours |
Q51842347 | How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. |
Q53038960 | Intra-arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma. |
Q37124855 | Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. |
Q39863380 | Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. |
Q36738649 | Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma |
Q26797643 | Multimodality Management for Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma |
Q97539487 | Neoadjuvant therapy and immunotherapy strategies for hepatocellular carcinoma |
Q64987573 | Network meta-analysis of treatment regimens for inoperable advanced hepatocellular carcinoma with portal vein invasion. |
Q41316719 | Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma |
Q90288434 | Patients with Barcelona Clinic Liver Cancer Stages B and C Hepatocellular Carcinoma: Time for a Subclassification |
Q48256935 | Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis |
Q46491963 | Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis |
Q37972806 | Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. |
Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
Q45369097 | Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). |
Q92643831 | Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A |
Q53172824 | Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. |
Q91879742 | Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial |
Q36230740 | Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study |
Q33379418 | Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases |
Q53466176 | Systemic treatment in advanced/metastatic hepatocellular carcinoma in the era of targeted therapy. |
Q43897398 | Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma |
Q26772299 | Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review |
Q42580930 | Which treatment modality should we choose for advanced hepatocellular carcinoma? |
Search more.